

Halothane for Surgical Removal of Pheochromocytoma

Plernchit Sirivannasandha, M.D.

*Department of Anesthesiology, Ramathibodi Hospital, Bangkok 10400, Thailand.

The anesthetic management of patients operated for pheochromocytoma was studied, using halothane as a principle anesthetic, desiring to support the use of halothane for this condition. It is because halothane is the only inhalation anesthetic most familiar to anesthesiologists and nurse anesthetists in Thailand.

Patients were 24 in series, scheduled for operation from January 1979 to February 1990. Fourteen were females and 10 males. All patients had typical symptoms and signs with VMA positive. Phenoxybenzamine was used as a pharmacologic preparation combined with inderal® (Prazosin) as indicated for directed arterial pressure. EKG, CVP, urine output are essential monitoring. Well recognized intraoperative complications, hypertension, arrhythmia and hypotension after tumor removal occurred but are easily managed. Arterial pressure was controlled by varying the inspired concentration of halothane. Sodium nitroprusside (SNP) was given in addition in only 10 cases with minimal dosage and short period of time. Arrhythmia appeared in 10 cases which is not serious, easily converted with 1-2 doses of xylocaine or propranolol. Hypotension after tumor removal is also easily corrected mostly by fluid replacement.

In conclusion, the successful use of halothane in 24 patients is confirmed the safety of halothane for pheochromocytoma, its sympathoadrenal depressant properties is very useful to modulate the characteristic hypertension during operation. Arrhythmogenic effect is not really a contraindication.

In fact, alert anesthesiologist, well understanding pathophysiology of the disease, effective monitoring and prompt management to the complication are more meaningful than anesthetic drugs.